FGF23 and cardiac hypertrophy: In this trial, the level of FGF23 will be modified by either the calcimimetic etelcalcetide (ETL) or alfacalcidol (ALFA) at a PTH clamp, and therefore will be able to test the causality of FGF23 reduction on cardiac hypertrophy and fibrosis.